EGFR and colorectal carcinoma: By leveraging the genomic biomarker data collected from consenting patients who participated in the Cancer and Leukemia Group B (CALGB)/SWOG 80405 trial and other relevant CRC datasets, here we investigate additional mechanisms of resistance to anti-EGFR and anti-VEGF containing therapies.